Cameron Brink achieves visual freedom with the EVO implantable lenses
Basketball Player
Basketball Player
Vision struggles on and off the court
Cameron Brink, a star on the women’s basketball team of Stanford University, faced the daily struggles of glasses and contacts, impacting both her personal and professional life.
EVO ICL: the game-changer
EVO ICL: the game-changer
Cameron's decision to correct her nearsightedness with the EVO ICL procedure was fueled by the desire to break free from the constraints of traditional vision correction methods. With EVO ICL, Cameron's life took a remarkable positive turn. "My life has changed for the better! I don't have to fumble with contacts anymore when I wake up or during the day, and my eyes aren't irritated anymore. Plus, I don't have to worry about losing lenses on the court!"
The differences post-EVO ICL are noticeable. In Cameron's words, "my eyes aren't irritated and dry like they were when I wore contacts. And I love waking up in the morning seeing clearly." Cameron emphasizes the life-changing benefits that extend beyond the basketball court. Choosing EVO ICL was not just about vision correction; it was a lifestyle choice. "The time I save each day! Living a life free of contacts was a huge selling point; as well as the fact that the EVO lens implant is reversible if I ever need it."
For those on the fence about EVO ICL, Cameron passionately encourages, "talk to your eye doctor today. It's truly a life-changing procedure!" Join her in experiencing the world with newfound clarity and confidence.
Ready to embrace a life without the hassle of glasses and contacts? Discover the possibilities with EVO ICL. Call an EVO advisor today to schedule an appointment with an eye doctor near you, and embark on your own journey towards visual freedom!
More Testimonials
Important Safety Information
EVO & EVO TICL is designed for the correction of moderate to high near-sightedness (-0.5 to -18.0 dioptres (D)) and the reduction of near-sightedness in patients with up to -18 dioptres (D) of near-sightedness with less than or equal to 6.0 dioptres (D) of astigmatism. It is indicated for patients who are 21 to 60 years of age. In order to be sure that your surgeon will use a EVO with the most adequate power for your eye, your near-sightedness should be stable for at least a year before undergoing eye surgery. EVO surgery has been documented to safely and effectively correct near-sightedness between -0.5 dioptres (D) to -18.0 dioptres (D) and partially correct near-sightedness up to -18 dioptres in eyes with up to 6.0(D) of astigmatism. If you have near-sightedness within these ranges, EVO surgery may improve your distance vision without eyeglasses or contact lenses. EVO surgery does not eliminate the need for reading glasses, even if you have never worn them before. The EVO represents an alternative to other refractive surgeries including, laser assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), incisional surgeries, or other means to correct myopia such as contact lenses and eye glasses. EVO is not intended to correct any astigmatism you may have. Implantation of the EVO is a surgical procedure, and as such, carries potentially serious risks. Please discuss the risks with your eye care provider. The following represent potential complications/adverse events reported in conjunction with refractive surgery in general: conjunctival irritation, acute corneal swelling, persistent corneal swelling, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphaema (blood in the eye), hypopyon (pus in the eye), eye infection, EVO Visian ICL dislocation, macular oedema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering EVO surgery you should have a complete eye examination and talk with your eye care professional about EVO surgery, especially the potential benefits, risks and complications. You should discuss the time needed for healing after surgery.
Important Safety Information
Latin America
संदर्भ
1Visian ICL Patient Information Booklet
2Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46.
3Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
4Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.
5aLee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.
5bParkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.